|Post IPO Valuation|
|Venture Round, 3/2011 ||$1M|
|Venture Round, 3/2012 ||$1.05M|
|Venture Round, 11/2012 ||$815k|
|Venture Round, 7/2013 ||$3M|
|Venture Round, 11/2013 ||$1M|
|Venture Round, 11/2013 ||$13.7M|
|POST IPO FUNDING TOTAL||$20.3M|
|Post IPO Equity, 4/2014 ||$20.3M|
Headquartered in New York, Alliqua, Inc., (OTCBB:ALQA) is a biomedical company focused on the development, manufacturing and marketing of its own proprietary products, utilizing its existing technology portfolio. The company currently markets its own proprietary brands of wound dressings: SilverSeal® Hydrogel, an antimicrobial dressing; and Hydress® a moist wound dressing. We intend to pursue projects in the fields of active ingredient and transdermal drug delivery, as well as advanced wound care.
Alliqua’s core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin. Transdermal delivery has multiple advantages over conventional oral and injection delivery including: Avoidance of hepatic first pass metabolism causing less stress on the liver; Non-invasive nature; Improved patient compliance; Discontinuation of administration by removal of the system; Lower dosage; No dependence on different metabolic rates of individuals; and No interaction with the gastrointestinal system.
In addition, Alliqua’s patch technology can be utilized for the delivery of many drugs, including various proteins that have, until now, necessitated injections or intravenous infusions.
Alliqua intends to capitalize on its technology’s other intrinsic benefits in various market verticals in the healthcare industry, including: wound healing, medical diagnostics and cosmeceuticals.